Drug
Eyp 1901
Eyp 1901: highest development phase Phase 3, developed by EyePoint Pharmaceuticals, Inc.. 2 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- EyePoint Pharmaceuticals, Inc.
Trials
| Drug | Phase | Indication |
|---|---|---|
| EYP-1901 NCT06668064 | Phase 3 | Wet Age Related Macular Degeneration |
| EYP-1901 NCT06683742 | Phase 3 | Wet Age Related Macular Degeneration |
Latest
No recent events.
Follow Eyp 1901 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.